The burden of atrial fibrillation: Should we abandon antiarrhythmic drug therapy?

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 9, Issue 4, 2004, Pages 257-262

  Dorian, Paul ^a   Mangat, Iqwal ^a   Pinter, Arnold ^a   Korley, Victoria ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Antiarrhythmic agents; Atrial fibrillation; Rate control; Rhythm control

Indexed keywords

2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; AMIODARONE; ANTIARRHYTHMIC AGENT; AZD 7009; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DOFETILIDE; DRONEDARONE; FLECAINIDE; IBUTILIDE; POTASSIUM CHANNEL BLOCKING AGENT; PROPAFENONE; RSD 1235; S 20951; S 9947; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; UNCLASSIFIED DRUG;

AGE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; HEART ATRIUM FIBRILLATION; HEART MUSCLE REFRACTORY PERIOD; HEART PROARRHYTHMIA; HEART RATE; HEART RHYTHM; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FUNCTION; HUMAN; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINUS RHYTHM; SYMPTOMATOLOGY;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CLINICAL TRIALS; COST OF ILLNESS; HEART RATE; HUMANS; TREATMENT OUTCOME;

EID: 12344322689     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840400900405     Document Type: Review

References (41)

1. Dorian P, Jung W, Newman D, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: Implications for the assessment of investigational therapy. J Am Coll Cardiol 36:1303-1309, 2000
2. Raquette M, Roy D, Talajic M, et al. Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation. Am J Cardiol 86:764-768, 2000
3. Humphries KH, Kerr CR, Connolly SJ, et al. New-onset atrial fibrillation: Sex differences in presentation, treatment, and outcome. Circulation 103:2365-2370, 2001
4. Wyse DG, Waldo AL, DiMarco JP, et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825-1833, 2002
5. Hagens VE, Ranchor AV, Van Sonderen E, et al. RACE Study Group. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol 43:241-247, 2004
6. Gronefeld GC, Lilienthal J, Kuck KH, et al. Pharmacological Intervention in Atrial Fibrillation (PIAF) Study Investigators. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. Eur Heart J 24:1430-1436, 2003
7. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 98:946-952, 1998
8. Carlsson J, Miketic S, Windeler J, et al. STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 41:1690-1696, 2003
9. Van Gelder IC, Hagens VE, Bosker HA, et al. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347:1834-1840, 2002
10. Lip GY, Hart RG, Conway DS. Antithrombotic therapy for atrial fibrillation. BMJ 325:1022-1025, 2002
11. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: An individual patient meta-analysis. JAMA 288:2441-2448, 2002
12. Cha YM, Redfield MM, Shen WK, et al. Atrial fibrillation and ventricular dysfunction: A vicious electromechanical cycle. Circulation 109:2839-2843, 2004
13. Verma A, Newman D, Geist M, et al. Effects of rhythm regularization and rate control in improving left ventricular function in atrial fibrillation patients undergoing atrioventricular nodal ablation. Can J Cardiol 17:437-445, 2001
14. Pinter A, Dorian P, Paquette M, et al. Left ventricular performance during acute rate control in atrial fibrillation: The importance of heart rate and agent used. J Cardiovasc Pharmacol Ther 8:17-24, 2003
15. Wood MA, Brown-Mahoney C, Kay N, Ellenbogen K. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: A meta-analysis. Circulation 101:1138-1144, 2000
16. Roy D. Rationale for the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Card Electrophysiol Rev 7:208-210, 2003
17. Dorian P, Paquette M, Newman D, et al. Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am Heart J 143:984-990, 2002
18. Singh SN, Singh BN. Sotalol amiodarone (atrial) fibrillation efficacy trial (SAFE-T). Presented at: the North American Society of Pacing and Electrophysiology 24th Annual Scientific Sessions; Washington, DC; May 14-17, 2003. Available at: http://www.naspe.oscsi.com/index. php?action=detail&id=7 (accessed October 21, 2004)
19. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 342:913-920, 2000
20. Fuster V, Ryden LE, Asinger RW, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation); North American Society of Pacing and Electrophysiology. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 104:2118-2150, 2001
21. Van Gelder IC, Crijns HJ, van Gilst WH, et al. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 64:1317-1321, 1989
22. Clementy J, Dulhoste MN, Laiter C, et al. Flecainide acetate in the prevention of paroxysmal atrial fibrillation: A nine-month follow-up of more than 500 patients. Am J Cardiol 70:44A-49A, 1992
23. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 342:913-920, 2000
24. AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: An AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 42:20-29, 2003
25. Hohnloser SH, Kuck KH. Randomized trial of rhythm or rate control in atrial fibrillation: The Pharmacological Intervention in Atrial Fibrillation Trial (PIAF). Eur Heart J 22:801-802, 2001
26. + current similar to Kv1.5 cloned channel currents. Circ Res 73:1061-1076, 1993
27. Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: Comparative efficacy and results of trials. Am J Cardiol 91:15D-26D, 2003
28. Roden DM, Balser JR, George AL Jr, et al. Cardiac ion channels. Annu Rev Physiol 64:431-475, 2002
29. KAch class Ic drugs and beta-blockers in pigs. Med Sci Monit 10:BR221-228, 2004
30. (Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide. Naunyn Schmiedebergs Arch Pharmacol 366:482-487, 2002
31. Li D, Zhang L, Kneller J, et al. Potential ionic mechanism for repolarization differences between canine right and left atrium. Circ Res 88:1168-1175, 2001
32. Schram G, Pourrier M, Melnyk P, et al. Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function. Circ Res 90:939-950, 2002
33. +-channel blocker AVE0118 in anesthetized pigs. Cardiovasc Res 60:298-306, 2003
34. Courtemanche M, Ramirez RJ, Nattel S. Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: Insights from a mathematical model. Cardiovasc Res 42:477-489, 1999
35. Blaauw Y, Goegelein H, Duytschaever M, et al. Synergistic class III action of blockade of Ikur/Ito (AVE 0118) and IKr (dofetilide/ibutilide) in electrically remodeled atria of the goat. Circulation 108(suppl IV):IV-84, 2004
36. Lee SD, Newman D, Ham M, et al. Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: Elimination of reverse use dependence. J Am Coll Cardiol 29:100-105, 1997
37. Nattel S, Khairy P, Roy D, et al. New approaches to atrial fibrillation management: A critical review of a rapidly evolving field. Drugs 62:2377-2397, 2002
38. Paulsson F, Jacobson I, Carlsson L. AZD7009-a new atrial antifibrillatory compound that blocks recombinant nHav 1.5 and potassium channels. Eur Heart J 25(Abstract Suppl):479 Abs 2285, 2004
39. Goldstein RN, Khrestian C, Carlsson L, et al. AZD7009: A new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol (in press)
40. Roy D, Beatch G, Steill I, et al. CRAFT Investigators. RSD1235 rapidly and effectively terminates atrial fibrillation. Eur Heart J 24:720, 2003 (abstract 3699)
41. Paulsson F, Jacobson I, Carlsson L. AZD7009-a new atrial antifibrillatory compound that blocks recombinant nHav 1.5 and potassium channels. Eur Heart J 25(Abstract Suppl):479 Abs 2285, 2004